Maria Gion, MD, Ramón y Cajal University Hospital, Madrid, Spain, outlines preliminary results from the Phase IIa PATHFINDER trial (NCT04464174) of ipatasertib, a pan-AKT inhibitor, combination with non-taxane chemotherapies for patients with previously treated advanced triple-negative breast cancer (aTNBC). Whilst the combination of this agent with capecitabine or eribulin was very well-tolerated, ipatasertib with carboplatin and gemcitabine led to hematological toxicities such as neutropenia and thrombocytopenia. Preliminary efficacy results showed a signal of activity, mainly for eribulin and ipatasertib, achieving a median progression free survival (PFS) of 3.8 months. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
